521284-19-5

Basic information

• Product Name: (alphaR)-alpha-Hydroxy-N-[2-(4-nitrophenyl)ethyl]benzeneacetamide
• Synonyms: (alphaR)-alpha-Hydroxy-N-[2-(4-nitrophenyl)ethyl]benzeneacetamide;BenzeneacetaMide, a-hydroxy-N-[2-(4-nitrophenyl)ethyl]-, (aR)-;BenzeneacetaMide, -hydroxy-N-[2-(4-nitrophenyl)ethyl]-, (R)-;R-a-hydroxy-N-[2-(4-nitrophenyl)ethyl]- BenzeneacetaMide;R-alpha-hydroxy-N-[2-(4-nitrophenyl)ethyl]- BenzeneacetaMide;(R)-N-(4-nitrophenethyl)-2-hydroxy-2-phenylacetamide;(R)-2-Hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide;Mirabegron INT 1
• CAS NO: 521284-19-5
• Molecular Formula: C₁₆H₁₆N₂O₄
• Molecular Weight: 300.30924
• EINECS: 300-560-8
• Product Categories: CMLLYL
• Mol File: 521284-19-5.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 584.8±50.0 °C(Predicted)
• Appearance: /
• Density: 1.294
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 12.50±0.20(Predicted)
• CAS DataBase Reference: (alphaR)-alpha-Hydroxy-N-[2-(4-nitrophenyl)ethyl]benzeneacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: (alphaR)-alpha-Hydroxy-N-[2-(4-nitrophenyl)ethyl]benzeneacetamide(521284-19-5)
• EPA Substance Registry System: (alphaR)-alpha-Hydroxy-N-[2-(4-nitrophenyl)ethyl]benzeneacetamide(521284-19-5)

Safety Data

• Hazardous Substances Data: 521284-19-5(Hazardous Substances Data)

Usage

Description

(alphaR)-alpha-Hydroxy-N-[2-(4-nitrophenyl)ethyl]benzeneacetamide is an organic compound belonging to the class of amides. It is characterized by its unique molecular structure, which includes a hydroxyl group, a nitrophenylethyl group, and a benzeneacetamide moiety. (alphaR)-alpha-Hydroxy-N-[2-(4-nitrophenyl)ethyl]benzeneacetamide is known for its potential applications in various fields, particularly in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
(alphaR)-alpha-Hydroxy-N-[2-(4-nitrophenyl)ethyl]benzeneacetamide is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure allows it to serve as a building block in the development of new medications with potential therapeutic benefits.
Used in the Synthesis of (Aminothiazolyl)acetanilide Derivatives:
In the field of diabetes treatment, (alphaR)-alpha-Hydroxy-N-[2-(4-nitrophenyl)ethyl]benzeneacetamide is used as an intermediate in the preparation of (aminothiazolyl)acetanilide derivatives. These derivatives are synthesized through coupling reactions and have shown promise in the treatment of diabetes, offering potential benefits to patients suffering from this chronic condition.

InChI:InChI=1S/C16H16N2O4/c19-15(13-4-2-1-3-5-13)16(20)17-11-10-12-6-8-14(9-7-12)18(21)22/h1-9,15,19H,10-11H2,(H,17,20)/t15-/m1/s1

Upstream product

• 611-71-2 (R)-Mandelic Acid 
• 29968-78-3 2-(4-nitrophenyl)ethylamine monohydrochloride 
• 24954-67-4 2-(p-nitrophenyl)ethylamine 
• 54385-47-6 (R)-Mandelsaeure, Natrium-Salz 
• 611-73-4 Benzoylformic acid 
• 98-86-2 acetophenone 
• 20698-91-3 (R)-methyl mandelate 
• 54256-33-6 (R)-(-)-5-phenyl-1,3-dioxolane-2,4-dione 

Downstream Products

• 521284-21-9 (R)-2-[[2′-(4-nitrophenyl)ethyl]amino]-1-phenylethanol hydrochloride 
• 223673-34-5 (R)-2-(4-nitrophenylethylamino)-1-phenylethan-1-ol hydrochloride 
• 391901-45-4 YM-208876 
• 223673-61-8 (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide 
• 223673-35-6 ((2R)-2-hydroxy-2-phenylethyl)-[2-(4-nitrophenyl)ethyl]carbamic acid tert-butyl ester 
• 223673-36-7 (R)-(4-aminophenylethyl)(2-hydroxy-2-phenylethyl)carbamic acid tert-butyl ester 
• 521284-22-0 (R)-2-[ [2-(4-aminophenyl)ethyl]-amino]-1-phenylethanol monohydrochloride 

Relevant articles and documents

Concise Synthesis of Key Intermediate of Mirabegron via a Mixed Anhydride Method

An efficiently scalable synthesis of key intermediate toward mirabegron has been developed via a mixed anhydride method, employing PivCl instead of EDCI and HOBt. The developed process produced (R)-2-hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide (10) in 91.5-92.3% yield and >99.0% HPLC purity under mild conditions. During this process, a side reaction induced by triethylamine hydrochloride was discovered and investigated, which was ultimately avoided by executing the reaction in a biphasic solvent system.

A method for preparing milamila beilong

The invention discloses a method for preparing milamila beilong, relates to the technical field of pharmaceutical, comprising the following steps: R - mandelic acid and P ethylamine under high-temperature to amide condensation reaction, to obtain the intermediate (R)- 2 - hydroxy - N - (4 - nitrophenyl ethyl) - 2 - phenyl acetamide; then diisobutyl hydrogenated aluminum reducing amide carbonyl, to obtain the intermediate (R)- 2 - ((4 - nitrophenyl ethyl) amino) - 1 - phenyl ethanol hydrochloride; ammonium formate - Pd/C by nitro reduction system, to obtain the intermediate (R)- 2 - ((4 - amino ethyl) amino) - 1 - phenyl ethanol; finally with the amino thiazole acetic acid to generate a condensation reaction, to obtain milamila beilong. The invention prepared milamila beilong purity is good, high yield, synthetic line few steps, conditions is mild and controllable, the operation is simple, low cost, and is suitable for industrial production, and with extensive prospect and industrial application value.

Aryl or heteroaryl substituted pyrrolidine amide derivatives and application thereof

The invention discloses aryl or heteroaryl substituted pyrrolidine amide derivatives and an application thereof, in particular to a novel aryl or heteroaryl substituted pyrrolidine amide derivative and a pharmaceutical composition containing the same, which can be used for activating beta3-adrenergic receptor. The invention also relates to a method for preparing the compounds and pharmaceutical compositions, as well as an application thereof in preparing drugs for treating diseases or symptoms mediated by beta3-adrenergic receptor, and especially for treating the overactive bladder.